BIOCARDIA (OTCMKTS:BCDA) Files An 8-K Entry into a Material Definitive Agreement

BIOCARDIA (OTCMKTS:BCDA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01     Entry Into a Material Definitive Agreement.

Story continues below

On June 17, 2020, BioCardia, Inc. (the “Company,” “us” or “we”) entered into an underwriting agreement (the “Underwriting Agreement”) with A.G.P./Alliance Global Partners (“AGP”), as representative (the “Representative”) for the several underwriters named in Schedule I thereto (the “Underwriters”), relating to the public offering (the “Offering”) by the Company of an aggregate of 4,762,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company granted the Underwriters a 45-day option to purchase up to 714,190 additional shares of Common Stock to cover over-allotments. Such option was exercised in full on June 18, 2020.

On June 19, 2020, the Offering closed and the Company completed the sale and issuance of an aggregate of 5,476,190 shares of Common Stock. The Common Stock was offered and sold to the public to the Company’s registration statement on Form S-1 (File No. 333-236404), filed by the Company with the Securities and Exchange Commission (the “SEC”) to the Securities Act of 1933, as amended (the “Securities Act”), on February 12, 2020, as amended, and which became effective on June 16, 2020. The offering price to the public was $2.10 per share of Common Stock. After deducting underwriting discounts and commissions and estimated offering expenses payable by us, we expect to realize net proceeds of approximately $10.3 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to, completing enrollment in the ongoing CardiAMP Cell Therapy pivotal trial for the treatment of heart failure, the funding of clinical development and pursuing regulatory approval for our product candidates.

Certain of our directors or entities affiliated with such persons have agreed to purchase an aggregate of 428,550 shares of common stock in the Offering on the same terms as those offered to the public.

The Underwriting Agreement contains customary representations, warranties, and covenants by the Company. It also provides for customary indemnification by each of the Company and the Underwriters, severally and not jointly, for losses or damages arising out of or in connection with the Offering, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. In addition, to the terms of the Underwriting Agreement, certain existing stockholders and each of the Company’s directors and executive officers have entered into “lock-up” agreements with the Underwriters that generally prohibit the sale, transfer, or other disposition of securities of the Company for a period of at least 90 days following June 17, 2020 without the prior written consent of the Representative, subject to customary exceptions.

The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety to the full text of the form of Underwriting Agreement, a copy of which is filed as Exhibit 1.1 and incorporated by reference herein. The provisions of the Underwriting Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to the Underwriting Agreement and the Underwriting Agreement is not intended as a document for investors or the public to obtain factual information about the current state of affairs of the parties to the Underwriting Agreement. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the SEC.

The final prospectus relating to the Offering has been filed with the SEC and is available on the SEC’s web site at Copies of the final prospectus relating to the offering may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 at (212) 813-1047, or from the above-mentioned SEC website.

Item 8.01     Other Events.

In connection with the Offering, on June 17, 2020 the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits


BioCardia, Inc. Exhibit
EX-1.1 2 ex_190859.htm EXHIBIT 1.1 ex_190859.htm Exhibit 1.1                       UNDERWRITING AGREEMENT   between   BioCardia,…
To view the full exhibit click here


BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.

An ad to help with our costs